EICHORCondition: Type 1 Diabetes · Sponsor: Sanofi
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general information on patients with stage 2 T1D and further information on the long-term effects of TZIELD® in patients with Stage 2 T1D, treated as per standard of care.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610 · Contact-US@sanofi.com
Always discuss trial participation with your own doctor first.
| University of California Los Angeles Health- Site Number : 8400020 | Los Angeles, California, United States | Recruiting |
| University of California San Francisco - Mission Bay- Site Number : 8400005 | San Francisco, California, United States | Recruiting |
| University of Colorado Hospital- Site Number : 8400026 | Aurora, Colorado, United States | Recruiting |
| Yale University School of Medicine- Site Number : 8400025 | New Haven, Connecticut, United States | Recruiting |
| University of Florida Health- Site Number : 8400035 | Gainesville, Florida, United States | Recruiting |
| Nemours Children's Speciality Care- Jacksonville- Site Number : 8400006 | Jacksonville, Florida, United States | Recruiting |
| University of Miami Miller School of Medicine- Site Number : 8400037 | Miami, Florida, United States | Recruiting |
| Nicklaus Children's Hospital - Miami - Southwest 62nd Avenue- Site Number : 8400034 | Miami, Florida, United States | Recruiting |
| University of South Florida- Site Number : 8400022 | Tampa, Florida, United States | Recruiting |
| Midtown Medical Center - Columbus- Site Number : 8400013 | Columbus, Georgia, United States | Recruiting |
| University of Chicago Medical Center- Site Number : 8400017 | Chicago, Illinois, United States | Recruiting |
| Indiana University Health Riley Hospital for Children- Site Number : 8400004 | Indianapolis, Indiana, United States | Recruiting |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06481904